-

NUAI Investor Alert: New Era Energy & Digital Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Concealed Fraudulent Scheme: Levi & Korsinsky

Notice to Pension Funds, Asset Managers, and Fiduciaries

NEW YORK--(BUSINESS WIRE)--Institutional investors holding positions in New Era Energy & Digital, Inc. (NASDAQ: NUAI) during the period from November 6, 2024 through December 29, 2025 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Shares of NUAI declined 41%, a loss of $1.87 per share, following reports that the New Mexico Attorney General had filed a lawsuit alleging the Company orchestrated a fraudulent oil-and-gas scheme. The Court has set June 1, 2026 as the deadline to apply for lead plaintiff appointment.

Notice to Institutional Holders

Pension funds, mutual funds, endowments, and asset managers that held NUAI securities during the Class Period face particular considerations. A securities class action has been filed alleging New Era Energy and certain officers made materially false and misleading statements about the Company's progress on its flagship Texas Critical Data Centers project and concealed involvement in a scheme to siphon revenue from oil and gas wells while evading environmental cleanup obligations. Fiduciaries with oversight of portfolios that included NUAI may need to assess whether pursuing recovery is consistent with their duties to beneficiaries.

Fiduciary Obligations and Recovery Options

  • Institutional holders with losses in NUAI may have fiduciary obligations to evaluate participation in available recovery mechanisms
  • Lead plaintiff appointment gives institutional investors direct oversight of litigation strategy, settlement negotiations, and counsel selection
  • Serving as lead plaintiff does not require out-of-pocket expenditures; securities class actions are prosecuted on a contingency basis
  • Institutional investors with the largest documented losses are typically best positioned for lead plaintiff appointment under the PSLRA
  • Absent class members retain the right to participate in any recovery without serving as lead plaintiff
  • Portfolio monitoring services can assist fiduciaries in identifying and tracking claims across holdings

ERISA and Fiduciary Considerations

For ERISA-governed plans that held NUAI shares, the Department of Labor has indicated that plan fiduciaries should consider participation in securities class actions as part of their duty of prudence. Failure to evaluate potential recoveries may itself raise fiduciary questions. The action contends that New Era Energy overstated permitting progress for its data center project while the Company was allegedly involved in related-party well transfers and strategic bankruptcies designed to avoid millions in environmental liabilities.

Contact us for institutional recovery options or call Joseph E. Levi, Esq. at (212) 363-7500.

Portfolio Impact Assessment

The corrective disclosures in this matter occurred in two waves. On December 12, 2025, shares fell 6.9% after a research report questioned the Company's permitting claims and its CEO's track record. On December 29, 2025, shares fell an additional 41% after reports surfaced that the New Mexico Attorney General had sued the Company, its subsidiary Solis Partners, and its CEO, alleging a fraudulent scheme involving hundreds of oil and gas wells. Institutional holders who acquired shares at prices inflated by the alleged misrepresentations may be entitled to recover the artificial inflation component of their purchase price.

"Institutional investors play a critical role in securities class actions. Their participation as lead plaintiff helps ensure vigorous prosecution of claims and meaningful accountability for alleged disclosure failures that harmed all shareholders." -- Joseph E. Levi, Esq.

Request an institutional investor loss assessment or contact Joseph E. Levi, Esq. at (212) 363-7500.

INSTITUTIONAL INVESTOR REPRESENTATION -- Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the NUAI Lawsuit

Q: When did New Era Energy allegedly mislead investors? A: The Complaint alleges the fraud began as early as November 6, 2024 and continued until the truth emerged beginning on December 12 and continuing through December 29, 2025.

Q: How much did NUAI stock drop? A: Following the Fuzzy Panda Research report, shares fell approximately 6.9% on December 12, 2025. Shares fell a further 41% on December 29, 2025 following Hunterbrook Media’s report.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

Q: Has Levi & Korsinsky handled similar cases before? A: Yes, including securities class actions involving revenue inflation, earnings guidance fraud, dividend misrepresentation, and executive misconduct across numerous industries.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:NUAI

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

SHAK Investor Alert: Levi & Korsinsky Investigates Shake Shack (SHAK) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shake Shack (NYSE: SHAK) lost approximately 9-10% of its value today after the company cut FY 2026 restaurant-level profit margin guidance from 23-23.5% to 22-23% and trimmed quarterly guidance from 24-24.5% to only 22-23%. Shareholders who lost money on SHAK are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.On May 7, 2026 -- just 26 days before today'...

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum’s June 1, 2026 Form 8-K, which...

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submi...
Back to Newsroom